Patricia Weiser, Pharm.D.

Vtama is a steroid-free cream that works by targeting the aryl hydrocarbon receptor, which plays a role in regulating immune responses.

Despite its efficacy, PrEP remains underutilized compared to the need for it. High costs are among the barriers to PrEP use, along with limited knowledge among clinicians, lack of health insurance, stigma, and underestimation of personal HIV risk.

People with moderate or severe hemophilia had worse joint status, lower pain thresholds, and poorer quality of life compared with people with mild hemophilia or healthy controls.

Pfizer and BioNTech released positive top-line data for their mRNA-based combination vaccine that targets influenza and COVID-19.

Results of this prospective cohort study fits with other evidence showing no association between COVID-19 vaccination and miscarriage.

Recent data found that extreme heat is projected to lead to a significantly higher burden of excess cardiovascular deaths in the United States by midcentury (2036–2065), with elderly adults and non-Hispanic Black adults being most affected.

The self-administered nasal spray may increase vaccination rates.

The mean lag time between FDA approval and insurance coverage for 89 cancer drugs ranged from 2.3 months to 8.2 months. But cancer drugs approved more recently were more likely to have shorter coverage lags.

Patients taking Mounjaro after a lifestyle intervention saw a weight reduction of almost 20%.

Coadministration of flu and COVID-19 vaccines is safe and effective, according to findings published recently in JAMA Network Open, and Moderna report a strong immune response to its experimental vaccine that would combine flu and COVID-19 vaccination into a single shot.

Researchers identified age and insurance type as significant factors in viral suppression in patient with HIV because of their impact on patient adherence.

The findings reported in JAMA Cardiology suggest that Entresto is more cost effective in patients with heart failure with lower ejection fractions.

Patients who continued with their rheumatoid arthritis biologic medication tended to spend less on healthcare, had a lower chance of being hospitalized, and had shorter hospital stays.

Patients with heart failure and obesity who were administered semaglutide experienced better results — they reported fewer symptoms, felt less physically limited, lost more weight, and could walk longer in a 6-minute test.

The recent study also found that Jardiance for patients with heart failure with preserved ejection fraction could be cost-effective if discounted by 29%.

Non-White patients who used copay cards were significantly more likely to encounter copay adjustment programs, such copay accumulators and maximizers, compared with their White counterparts.

This simulation study also showed that semaglutide was the most effective for weight loss, and researchers said, long-term, savings associated with potential lifelong health improvements may shift the balance of cost-effectiveness.

For most drugs, the statutory minimum discounts under the Inflation Reduction Act will not be enough to achieve the savings projected by the Congressional Budget Office.

Long-acting injection formulations of paliperidone improve health outcomes in adults with schizophrenia but that might not be enough to offset their substantial costs, new study finds.

The number of health plans that put in place restrictive policies that go beyond FDA-approved label is increasing, a new Tufts study finds.

Biosimilars that are interchangeable with Humira could provide more competition on price, a new analysis suggests.

Researchers say capping insulin costs at $35 a month has the potential to lower events and costs related to diabetes, such as amputations, vision loss, and heart attacks.

Researchers have been working on sorting out the causal direction of multiple sclerosis (MS) and depression. These findings suggest that depression can be a consequences of MS-related disability not the other way around.

Mutations in one locus were associated with a decrease in the median time until needing a walking aid of between 3.3 and 3.7 years.

70% of inflammatory bowel disease patients managed by in-system specialty pharmacies were adherent to their therapies, according to research findings.